Brexit
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.

Pharma Breathes Sigh Of Relief Over Brexit Deal
The ABPI and EFPIA give a cautious welcome, but are pleased it means "ongoing collaboration in key areas including scientific research and cooperation in areas like medicines safety."

Brexit Finally Here But Uncertainty Not Over For Biopharma
A free trade deal needs to be negotiated in record time and UK life sciences must face up to diverging from the EU.
Latest From Brexit
UK Government Promise For 2021: No Halting The Advance Of Healthtech Innovation Adoption
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.
UK Medtechs Determined To Exploit Digital Health Opportunity Born From The Pandemic
COVID-19 has forced a rethink in how care should be delivered. Healthcomms Consulting partner Dan Jones says it is an opportunity that must not be squandered.
The Times They Are A-Changin’: Opportunities In Medtech Regulation For The UK After Brexit
The turn of the year is a chance to reflect on times past and the future, to make resolutions and look ahead to changes for the better. With Brexit in mind, this is the time to prophesize on UK medtech’s immediate future.
UK/Canada Deal Lets Drug Agencies Avoid Brexit-Related Trade Disruption
An interim trade deal between the UK and Canada means that the regulators in these countries will carry on accepting each other’s batch testing and GMP certificates.
Top 20 EU Regulatory Stories Of 2020: Nightmare Year With Brexit, MDR Implementation … And COVID-19
Not only might each day feel like Groundhog Day now – with COVID-19 limiting everyone’s activities. But early 2021 puts the EU medtech sector in a similar place to early 2020. So what has changed?
UK BIA To Push For Post-Brexit Regulatory Agreement With EU
There may not be a great deal in the new UK-EU trade and cooperation deal for the life sciences industry but a new working group could act as the forum for constructive discussions on regulatory cooperation.
UK All-Party Report Assesses Brexit Medtech Impact While Germany Worries Over Border Delays
Government and industry in the UK are determined to make the best of the Brexit free trade deal, but German medtechs are eager for trade flow practicalities to be prioritized.
UK Explains New ‘Reliance’ Routes To Approval Based On EU Dossiers
Companies seeking marketing authorizations in the UK or Great Britain will be able to make use of two new “reliance” procedures offering regulatory assessment times of 67 days or less if their products have already gone through the EU centralized or decentralized approval systems.
UK Health Care Industry Must Adjust To EU Free Trade Deal
“No deal” was finally off the table for UK trade in goods with the EU after an 11th hour free trade agreement was reached. But for the UK, the decision effectively means a “hard Brexit.”
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.